Ketof

Ketotifen, the active ingredient in Ketof, is an antihistamine (H1 receptor antagonist) presented as an oral tablet for oral use. It is employed to manage allergic conditions such as rhinitis, conjunctivitis, and to aid in asthma prophylaxis in patients requiring mast‑cell stabilization.

GNH USA supplies Ketof as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, with distribution aligned to EU regulatory standards. The product meets stringent quality specifications and is available for bulk procurement across multiple regions.

Ketotifen is used in the management of allergic disorders by targeting histamine‑mediated pathways.

Allergic rhinitis: relief of nasal congestion, sneezing and itching. Allergic conjunctivitis: reduction of eye redness, itching and tearing. Asthma prophylaxis: prevention of bronchial hyper‑responsiveness and mast‑cell mediated attacks.

Ketotifen may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Drowsiness or somnolence. - Dry mouth or throat. - Weight gain. - Headache. - Nausea. - Mild gastrointestinal discomfort.

Serious or Rare Side Effects: - Severe skin reactions, including Stevens‑Johnson syndrome. - Anaphylactic or anaphylactoid reactions. - Hepatotoxicity manifested by elevated liver enzymes. - Cardiac arrhythmias or palpitations. - Hematologic abnormalities such as neutropenia. - Visual disturbances or blurred vision.

Ketotifen should be used with consideration of individual health status and potential risks.

Pregnancy: consult a healthcare professional before use. Breastfeeding: weigh potential benefits against possible infant exposure. Elderly patients: monitor for increased sedation. Renal or hepatic impairment: dose adjustment may be required. Concomitant CNS depressants: avoid additive drowsiness. Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Ketotifen can interact with several drug classes, requiring careful management.

Major Interactions (Avoid): - Monoamine oxidase inhibitors (MAOIs): risk of exaggerated antihistaminic effects. - Potent CYP3A4 inhibitors (e.g., ketoconazole): may increase plasma concentrations. - CNS depressants (e.g., benzodiazepines): additive sedation.

Moderate Interactions (Monitor Closely):\n- Alcohol: may enhance drowsiness. - Anticholinergic agents: increase dry‑mouth risk. - Other antihistamines: potential for cumulative antihistaminic activity.